Kezar Life Sciences, Inc. (NASDAQ:KZR) Shares Sold by Wells Fargo & Company MN

Wells Fargo & Company MN trimmed its holdings in Kezar Life Sciences, Inc. (NASDAQ:KZR) by 92.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,177 shares of the company’s stock after selling 71,985 shares during the period. Wells Fargo & Company MN’s holdings in Kezar Life Sciences were worth $42,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also modified their holdings of the company. JPMorgan Chase & Co. increased its position in Kezar Life Sciences by 613.8% during the fourth quarter. JPMorgan Chase & Co. now owns 11,884 shares of the company’s stock worth $80,000 after purchasing an additional 10,219 shares during the last quarter. BML Capital Management LLC acquired a new stake in Kezar Life Sciences during the fourth quarter worth about $327,000. Finally, Peapod Lane Capital LLC acquired a new stake in Kezar Life Sciences during the fourth quarter worth about $833,000. 67.90% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, William Blair reiterated an “outperform” rating on shares of Kezar Life Sciences in a research report on Friday, February 28th.

Kezar Life Sciences Price Performance

Shares of KZR opened at $4.13 on Thursday. Kezar Life Sciences, Inc. has a 1-year low of $3.62 and a 1-year high of $9.18. The stock has a market cap of $30.17 million, a PE ratio of -0.31 and a beta of 0.61. The firm has a 50-day simple moving average of $4.70 and a two-hundred day simple moving average of $6.00. The company has a debt-to-equity ratio of 0.05, a current ratio of 7.65 and a quick ratio of 7.65.

Kezar Life Sciences (NASDAQ:KZR) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($2.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.56) by $0.29. As a group, analysts forecast that Kezar Life Sciences, Inc. will post -4.39 EPS for the current year.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.